Belizatinib

Dublin, April 21, 2021 (GLOBE NEWSWIRE) -- The "Global Anaplastic Lymphoma Kinase ALK Inhibitors Market, Drug Sales, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. The global anaplastic lymphoma kinase inhibitor market is going to witness high growth during the forecast period which is mainly attributed to the rise in prevalence of anaplastic lymphoma kinase positive cancers and high research and development activities in this sector. The rates at which conventional therapies are failing will further possess unmet need for the development of novel target therapies which will also drive the growth of the market. In addition to this, the robust clinical pipeline and their increasing application in different cancers will drive the market in coming years. Global Anaplastic Lymphoma Kinase ALK Inhibitors Market & Clinical Trials Insight 2026 Report Highlights: The progress made by science and technology in last few decades has led to the identification of several potential targets which can be utilized in the drug development process. The characterization of anaplastic lymphoma kinase (ALK) gene and their role in the development and progression of ALK positive cancer has transformed the cancer therapeutics market. The extensive research activities by the researchers have led to the development of novel anaplastic lymphoma kinase inhibitors which belongs to the class of tyrosine receptor kinase and are used in the management of cancer. Till now, multiple anaplastic lymphoma kinase inhibitors have been approved by the regulatory authorities and several others are present in clinical pipeline which are expected to enter the market in next few years. The advent of these drugs in the market has overcome the limitations of conventional therapies such as chemotherapy and radiotherapy. The high target ability and specificity of these inhibitors towards the cancer cells has enhanced the survival rates of cancer patients and also improved the quality of life of patients. Since the approval of first generation anaplastic lymphoma kinase inhibitor in the management of non-small cell lung cancer, researchers have indulge in research activities for the development of next generation inhibitors which can overcome the limitations and can efficiently cross the blood brain barrier for enhanced efficacy. Apart from this, several clinical trials are ongoing to evaluate the efficacy of these drugs in combination with other chemotherapeutic drugs and immune checkpoint inhibitors. The combinational therapy will increase the efficacy of the drug which can better combat the complexity of the cancer. Despite several advantages of anaplastic lymphoma kinase inhibitors in the management of cancer, there are several factors which restrain the growth of the market. The resistance to the drugs during 1-2 year of the therapy is one of the limiting factors which will act as a barrier to the market. Moreover, the high cost associated with the drug will also limit the availability of the drug and increases the financial toxicity on the patient and their families. Currently, US holds the top position in the global market and is expected to maintain its position over the forecast period mainly due to the presence of large pharmaceutical sector which actively invest in research and development activities as well as increasing funding by the government to promote research and development. Apart from this, other regions such Europe, Asia-Pacific and Japan are also expanding their markets to secure their position in the global market. The global anaplastic lymphoma kinase inhibitor market is going to witness high growth rate and is expected to double in next 5 years. Furthermore, the market will be flourished with next-generation ALK inhibitors as well as several combinational therapies in wide range of cancers including neuroblastoma, lymphoma and colorectal cancer. The report includes information about the patent expiration, dosage, price, sales and mechanism of currently approved anaplastic lymphoma kinase inhibitors. In addition to this, several emerging ALK inhibitors along with their clinical trials are also provided in the report. Key Topics Covered: 1. Introduction to Anaplastic Lymphoma Kinase (ALK) Inhibitors1.1 Overview1.2 History of Development 2. ALK Inhibitors as Cancer Therapeutics2.1 Need of ALK Inhibitors in Cancer Therapy2.2 ALK - Potential Target in Cancer Therapy2.3 Mechanism of Action 3. ALK Inhibitors in Lung Cancer3.1 Role of ALK Inhibitors in Lung Cancer3.2 On Going Research & Development 4. ALK Inhibitors in Neuroblastoma4.1 Role of ALK Inhibitor in Neuroblastoma4.2 On Going Clinical Research 5. ALK Inhibitors in Lymphoma5.1 Role of ALK in Lymphoma5.2 On Going Clinical Research 6. ALK Inhibitors in Other Cancers6.1 ALK Inhibitor in Colorectal Cancer6.2 ALK in Renal Cell Carcinoma6.3 ALK Inhibitor in Inflammatory Myofibroblastic Tumor 7. Crizotinib (Xalkori) - Clinical & Commercial Insight7.1 Overview7.2 Patents & Assignees7.3 Dosage & Price Analysis7.4 Sales Analysis 8. Certinib (Zykadia) - Clinical & Commercial Insight8.1 Overview8.2 Patents & Assignees8.3 Dosage & Price Analysis 9. Alectinib (Alecensa) - Clinical & Commercial Insight9.1 Overview9.2 Patents & Assignee9.3 Dosage & Price Analysis9.4 Sales Analysis 10. Brigatinib (Alunbrig) - Clinical & Commercial Insight10.1 Overview10.2 Patent Information10.3 Dosage & Price Analysis10.4 Sales Analysis 11. Lorlatinib (Lorbrena) - Clinical & Commercial Insight11.1 Overview11.2 Dosage, Patent & Price Analysis11.3 Sales Analysis 12. Emerging Novel ALK Inhibitors in Cancer12.1 Ensartinib12.2 Entrectinib (RXDX-101)12.3 TPX-013112.4 TQ-B313912.5 Belizatinib (TSR-011)12.6 CEP-3744012.7 Alkotinib 13. ALK Inhibitor Market Analysis - Clinical Trial Insight13.1 By Phase13.2 By Company13.3 By Country13.4 By Patient Segment 14. ALK Inhibitors Drug Market14.1 Current Market Scenario14.2 Global & Regional Market Analysis 15. ALK Inhibitor Drug Market by Product15.1 First Generation ALK Inhibitor15.2 Second Generation ALK Inhibitor15.3 Third Generation ALK Inhibitor 16. Anaplastic Lymphoma Kinase (ALK) Inhibitors Clinical Trials Insight16.1 Research16.2 Preclinical16.3 Phase-I16.4 Phase-I/II16.5 Phase-II16.6 Phase-III 17. Marketed Anaplastic Lymphoma Kinase (ALK) Inhibitors Clinical Insight17.1 ALUNBRIG17.2 Lorbrena/Lorviqua17.3 Alecensa17.4 Jikadia/ Zykadia17.5 Xalkori 18. ALK Inhibitor - On Going Research & Development18.1 Lorbrena Overcomes Xalkori as Front-Line Therapy in NSCLC18.2 Comparable Time to Treatment Deterioration of Lorlatinib & Crizotinib inPatients with NSCLC18.3 FDA Approved CDx Assay for Lorlatinib in ALK Positive NSCLC18.4 TPX-0131 Overcomes ALK Mutations in Preclinical Models 19. ALK Inhibitor Drug Market Future Prospects19.1 ALK Inhibitor Future Forecast19.2 Future Market Opportunity of ALK Inhibitor 20. ALK Inhibitor Drug Market Dynamics20.1 ALK Inhibitor Drug Market Favorable Parameters20.2 Barriers to ALK Inhibitor Drug Market 21. Competitive Landscape21.1 Astellas Pharma21.2 AstraZeneca21.3 Betta Pharmaceuticals21.4 GlaxoSmithKline21.5 Merck21.6 Novartis21.7 Pfizer21.8 Roche21.9 Takeda Pharmaceuticals21.10 Turning Point Therapeutics For more information about this report visit

U.S. FDA PDUFA action date for oral rolapitant is September 5, 2015 Bioequivalence of IV and oral rolapitant successfully demonstrated Data from Phase 3 NOVA trial of niraparib anticipated in Q4 2015 Cash and cash equivalents totaled $354 million as of June 30, 2015 WALTHAM, Mass., Aug. 6, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today reported operating results for second-quarter 2015 and provided an update on the Company's development programs. "TESARO continues to make significant progress in advancing its pipeline of product candidates, and preparations for the commercial launch of oral rolapitant are well underway to support product introduction in the fourth quarter," said Lonnie Moulder, CEO of TESARO. ? "We have established our medical science liaison, nurse educator, and regional sales leadership teams, and the build-out of our field sales organization is nearly complete. The second half of 2015 ?will be an exciting time for the Company, as we look ahead to the expected niraparib Phase 3 NOVA trial data in the fourth quarter of 2015, the NDA submission for IV rolapitant, and the initiation of our immuno-oncology clinical program in early 2016?." Recent Business Highlights The New Drug Application (NDA) for oral rolapitant is under review by the U.S. Food and Drug Administration (FDA), with a PDUFA goal date of September 5, 2015. Commercial preparations are well underway in support of a potential oral rolapitant product launch in the fourth quarter of 2015. The rolapitant bioequivalence trial successfully achieved its primary endpoint, demonstrating similar exposure for a dose of intravenous (IV) rolapitant as compared to a dose of oral rolapitant. Expansion of the TESARO commercial organization is ongoing, with sales management, medical science liaison, and nurse educator teams now in place and the build-out of the field sales team is nearly complete in preparation for launch. TESARO and Jiangsu Hengrui Medicine Co., Ltd. announced an exclusive license agreement for the development, registration, manufacture, and commercialization of rolapitant in China. Phase 3 data from the NOVA trial of niraparib for patients with high-grade serous, platinum-sensitive, relapsed ovarian cancer is expected in the fourth quarter of 2015, following completion of enrollment in both cohorts earlier this year. Enrollment of the QUADRA trial of niraparib is ongoing for the treatment of patients with ovarian cancer who have received three or more prior lines of chemotherapy. TESARO and Merck announced a collaboration and have finalized the protocol to evaluate the combination of niraparib plus Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical trial in patients with triple-negative breast cancer or ovarian cancer. Patient enrollment continues in the Phase 3 BRAVO trial of niraparib for the treatment of patients with breast cancer, and planning is ongoing in support of the initiation of a trial of niraparib in the first-line ovarian cancer setting (PRIMA). The Phase 1/2 AVANOVA three-arm trial of niraparib, comparing the tolerability and efficacy of niraparib plus bevacizumab versus bevacizumab versus niraparib in patients with ovarian cancer, continues to enroll in collaboration with The European Network for Gynaecological Oncological Trial groups (ENGOT). Patient enrollment continues in the Phase 1 study of niraparib plus chemotherapy in patients with Ewing's sarcoma in partnership with the Sarcoma Alliance for Research through Collaboration (SARC). The clinical activity of a fractionated dose of TSR-011 continues to be evaluated in ALK-positive patients who have not been previously treated with an ALK inhibitor, and a controlled release formulation is being evaluated within the ongoing Phase 1 study. Antibody drug candidates targeting PD-1, TIM-3, and LAG-3 continue to advance, and GLP toxicology studies are now underway for TSR-042. Second-Quarter 2015 Financial Results TESARO reported a net loss of $60.6 million, or ($1.51) per share, for the second quarter of 2015, compared to a net loss of $37.1 million, or ($1.03) per share, for the second quarter of 2014. Research and development expenses increased to $38.9 million for the second quarter of 2015, compared to $30.6 million for the second quarter of 2014, driven primarily by higher costs related to expanded development activities and increased headcount. General and administrative expenses increased to $16.8 million for the second quarter of 2015, compared to $5.6 million for the second quarter of 2014, primarily due to pre-launch commercial activities in support of oral rolapitant, increased headcount, and higher professional service fees. In-process research and development expense was $1.0 million in the quarter and related to a development milestone achieved for our immuno-oncology programs, compared to $0.9 million for the second quarter of 2014, which related to initiation of patient treatment within the BRAVO trial of niraparib. Operating expenses, as described above, include total non-cash, stock-based compensation expense of $5.5 million for the second quarter of 2015, compared to $3.1 million for the second quarter of 2014. Net interest expense increased to $3.9 million for the second quarter of 2015, primarily due to the accrual of interest payable and non-cash amortization of the debt discount associated with the 3.00% senior convertible notes due 2021, issued in September 2014. As of June 30, 2015, TESARO had approximately $354.4 million in cash and cash equivalents and approximately 40.0 million outstanding shares of common stock. TESARO continues to expect cash utilization to increase over the course of 2015 and to average in the mid-$50 million range per quarter for the remainder of 2015, excluding a $15 million milestone payment that will be due upon first commercial sale of rolapitant, which is expected in the fourth quarter. Corporate Objectives TESARO anticipates achieving the following key objectives: Launch oral rolapitant into the U.S. market in Q4 2015, pending approval by the FDA; Submit the NDA for IV rolapitant following the commercial launch of oral rolapitant; Submit the oral rolapitant Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in early 2016; Report data from the Phase 3 NOVA trial of niraparib in Q4 2015; Advance the QUADRA trial of niraparib as a treatment for patients with ovarian cancer who have received three or more prior lines of therapy and report initial data in early 2016; Advance the Phase 3 BRAVO trial of niraparib in breast cancer patients with germline BRCA mutations throughout 2015; Initiate niraparib/KEYTRUDA® (pembrolizumab) combination trial in partnership with Merck in Q4 2015; Initiate the clinical trial of niraparib in first line ovarian cancer (PRIMA) in Q4 2015; Continue to evaluate the clinical activity of a controlled release formulation of TSR-011 within the ongoing Phase 1 study; Advance the development of TSR-042 (anti-PD-1 antibody) to support submission of an Investigational New Drug (IND) application to the U.S. FDA in late 2015; and Advance the IND-enabling studies for the anti-TIM-3 clinical candidate. Today's Conference Call and Webcast TESARO will host a conference call to discuss the Company's second quarter operating results and provide an update on the Company's development programs today at 4:15 P.M. Eastern time. The accompanying slide presentation and live webcast of the conference call can be accessed by visiting the TESARO website at . The call can be accessed by dialing (877) 853-5334 (U.S. and Canada) or (970) 315-0307 (international). A replay of the webcast will be archived on the Company's website for 30 days following the call. About TESARO TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing, and commercializing safer and more effective therapeutics. For more information, visit . Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding our expected range of cash utilization for the remainder of 2015, our expectation to have Phase 3 NOVA data in the fourth quarter of 2015 and QUADRA data in early 2016, the expected timing of the rolapitant MAA filing, the NDA for rolapitant IV, and other regulatory filings with respect to our product candidates, the expected timing of the rolapitant commercial launch, the expected timing of data from our various clinical trials, our plans regarding future clinical trials with niraparib, statements regarding our various 2015 corporate objectives, the estimated time periods when we expect clinical trials to commence or be completed, and statements regarding our expectations about the timing of both the selection of clinical candidates from our immuno-oncology programs and the commencement of clinical testing for those candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the execution and completion of clinical trials, uncertainties surrounding the timing of availability of data from our clinical trials, ongoing discussions with and actions by regulatory authorities, patient accrual rates for clinical trials, and other matters that could affect the timing of availability of data from or initiation of our clinical trials, uncertainties regarding regulatory approvals, uncertainties regarding certain expenditures, and other matters that could affect the availability or commercial potential of our drug candidates. TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Annual Report on Form 10-K for the year ended December 31, 2014. TESARO, Inc. Unaudited Condensed Consolidated Statements of Operations (in thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2014 2015 2014 2015 Expenses: Research and development (1) $ 30,569 $ 38,930 $ 58,686 $ 72,475 General and administrative (1) 5,587 16,783 10,275 28,025 Acquired in-process research and development 900 1,000 17,900 1,000 Total expenses 37,056 56,713 86,861 101,500 Loss from operations (37,056) (56,713) (86,861) (101,500) Interest income (expense), net 5 (3,844) 10 (7,563) Net loss $ (37,051) $ (60,557) $ (86,851) $ (109,063) Net loss per share applicable to common stockholders - basic and diluted $ (1.03) $ (1.51) $ (2.45) $ (2.82) Weighted-average number of common shares used in net loss per share applicable to common stockholders - basic and diluted 35,982 40,008 35,422 38,667 (1) Expenses include the following amounts of non-cash stock-based compensation expense: Research and development $ 1,454 $ 2,211 $ 2,364 $ 4,025 General and administrative 1,648 3,249 3,276 5,356 TESARO, Inc. Unaudited Condensed Consolidated Balance Sheets (in thousands) December 31, 2014 June 30, 2015 Assets Current assets: Cash and cash equivalents $ 256,861 $ 354,369 Other current assets 1,735 2,871 Total current assets 258,596 357,240 Property and equipment, net 1,022 2,177 Other assets 4,284 3,960 Total assets $ 263,902 $ 363,377 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 6,089 $ 9,623 Accrued expenses 16,750 24,791 Other current liabilities 1,526 1,559 Total current liabilities 24,365 35,973 Convertible notes, net 115,481 119,685 Total liabilities 139,846 155,658 Total stockholders' equity 124,056 207,719 Total liabilities and stockholders' equity $ 263,902 $ 363,377 CONTACT: Investor/Media Contact: Jennifer Davis +1.781.325.1116 or jdavis@tesarobio.com Help employers find you! Check out all the jobs and post your resume.